<DOC>
	<DOCNO>NCT02582866</DOCNO>
	<brief_summary>Study conduct evaluate long-term safety tolerability lacosamide ( LCM ) patient receive LCM SP0994 [ NCT01465997 ] . The study enable collection additional monotherapy safety data , facilitate access treatment commercial availability monotherapy use .</brief_summary>
	<brief_title>A Clinical Study Investigate Long-term Use Lacosamide Monotherapy Subjects Who Completed Study SP0994</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>An Institutional Review Board /Institutional Ethics Committee approve write Informed Consent Form ( ICF ) sign date subject parent ( ) legal representative . The ICF specific Assent form , require , sign dated minor Subject/legal representative consider reliable capable adhere protocol , visit schedule , medication intake accord judgment investigator Subject complete Termination Visit SP0994 [ NCT01465997 ] treat lacosamide monotherapy Subject receive investigational drug use experimental device addition lacosamide ( LCM ) Subject experience seizure 3rd target dose ( i.e . LCM 600 mg/day ) SP0994 Subject require another Anti Epileptic Drug ( AED ) treatment seizure Subject meet `` must '' withdrawal criterion SP0994 Subject experience ongoing Serious Adverse Event SP0994 Female subject pregnant nursing , and/or woman childbearing potential surgically sterile , 2 year postmenopausal practice one highly effective method contraception , unless sexually abstinent , duration study</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Partial onset seizure</keyword>
	<keyword>Tonic-clonic seizure</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>AED</keyword>
</DOC>